We are focused on blocking fatty acid synthase (FASN) a key regulator of lipid synthesis, FASN activity is increased in certain diseases such as in the liver of patients with NASH and in certain tumor types. We believe that FASN provides an intervention point for clinical benefit.
Our lead product candidate, TVB-2640, is an oral, highly potent, selective and reversible, first-in-class inhibitor of FASN in clinical development. Phase 1 clinical studies showed that TVB-2640 inhibits de novo lipogenesis in cancer patients and reduces liver fat synthesis in people with characteristics of metabolic syndrome. Our current disease areas are NASH and oncology.